Generate Biomedicines, Inc.
GENB
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.68B
Close$
Share Statistics
| Market cap | $1.68 Billion |
|---|---|
| Enterprise Value | $1.60 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.98 |
| Beta | 0 |
| Outstanding Shares | 128,192,484 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -3.23 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | 3.68 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 0.16 |
Revenue Sources
No data
Insider Trades
Next Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.48
Average shareholder expectationRevenue Estimate
$5.28 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | 12,571▲ Infinity% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 72.41%▲ 72.41% |
|---|---|
| Total Invested | $1.16B |
| Investors Holding | 58▲ 58.00% |
ESG Score
No data
About Generate Biomedicines, Inc.
312 employees
CEO: Michael T. Nally Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modali...